For much of the history of nutraceuticals, ingredient selection has been guided by association: epidemiological observations, animal studies and small human trials showing that a given fibre or botanical correlates with a health outcome.
The mechanism, what the gut microbiome does with an ingredient, has largely remained a black box.
A London-based biotechnology company, Enbiosis Biotechnologies, is working to change that logic.
Their platform uses genome-scale metabolic models of gut bacteria and an AI retrosynthesis engine to predict which food-grade precursors will produce targeted health-promoting metabolites in a patient population's microbiome before clinical studies begin.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.